Gain Therapeutics, Inc. (GANX) company profile
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
About Gain Therapeutics
Pharmaceutical Preparations, SIC 2834
Gain Therapeutics is a clinical-stage biotechnology company that utilizes its computational discovery platform, Magellan, to identify novel allosteric binding sites on disease-causing proteins. The company focuses on developing small molecule therapeutics, known as structurally targeted allosteric regulators, to treat conditions associated with protein misfolding and dysfunction. Its research and pipeline target central nervous system disorders, lysosomal storage disorders, metabolic diseases, and oncology indications. The company's lead drug candidate, GT-02287, is being developed for the treatment of Parkinson's disease with or without GBA1 mutations. Gain Therapeutics advances its programs and targets through collaborations with academic research institutions and industry licensing or co-development partners.
The company operates at a clinical stage, conducting Phase 1 clinical studies in healthy volunteers and patients with Parkinson's disease in Australia. In addition, its intellectual property portfolio includes granted patents across the United States, Europe, Japan, China, and Canada. The provided text does not disclose the location of the company's headquarters.
Summary of the business section of Gain Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Gain Therapeutics, Inc.
- Headquarters
- Bethesda, MD
- Address
- 4800 Hampden Lane, Suite 200 20814
- Phone
- (301) 500-1556
- Website
- gaintherapeutics.com
- Employees
- 20, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young AG, Lugano, Switzerland
Stock & identifiers
- Ticker
- GANX
- Exchange
- Nasdaq
- IPO date
- Mar 22, 2021
- Shares outstanding
- 44M, Jul 31, 2026
- Public float
- $53.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1819411
- CUSIP
- 36269B105
- ISIN
- US36269B1052
- FIGI
- BBG00W7D7CJ9
- Share class FIGI
- BBG00W7D7CK7
- EIN
- 85-1726310
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gene Mack | CEO, President, Director | 14,400 |
| Jeanette Weidner | See Remarks | – |
| Gianluca Fuggetta | See Remark | – |
| Dov A. Goldstein Md | Director | – |
| Hans Peter Hasler | Director | – |
| Claude Nicaise | Director | – |
| Jeffrey Scott Riley | Director | 30,000 |
| Gwen A. Melincoff | Director | – |
| Khalid Islam | Director | 930,784 |
| Eric I. Richman | Director | 304,458 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Gene Mack Chief Executive Officer | $500.00K | $802.82K | $150.00K | $14.32K | $1.47M | +99% |
| Gianluca Fuggetta Principal Financial Officer | $241.35K | $82.00K | $21.72K | – | $345.07K | -6% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 22, 2021
- Securities offered
- 3,636,364
- Exchange
- Nasdaq
- First trading day
- Mar 19, 2021
- First-day close
- $12.20
- Lock-up ends (est.)
- Sep 15, 2021
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 20 full-time employees and one part-time employee.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 15, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 12, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 22, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 17, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?